Cytokines in rheumatoid arthritis: trials and tribulations

Nancy L. Carteron MD, FACR (Rheumatology Consultant)
{"title":"Cytokines in rheumatoid arthritis: trials and tribulations","authors":"Nancy L. Carteron MD, FACR (Rheumatology Consultant)","doi":"10.1016/S1357-4310(00)01757-3","DOIUrl":null,"url":null,"abstract":"<div><p>Biological agents that inhibit the activity of proinflammatory cytokines are being investigated for use in the treatment of rheumatoid arthritis. Thus far, two of these agents, both of which neutralize tumor necrosis factor α (TNF-α), have received US Food and Drug Administration approval for the treatment of the disease. Etanercept is a bioengineered fusion protein of the p75 soluble TNF receptor, and infliximab is a chimeric monoclonal antibody to TNF-α. Other agents that target proinflammatory cytokines are also being developed. By allowing earlier treatment and better-tolerated long-term therapy, biologics might help slow or prevent disease progression and joint destruction.</p></div>","PeriodicalId":79448,"journal":{"name":"Molecular medicine today","volume":"6 8","pages":"Pages 315-323"},"PeriodicalIF":0.0000,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1357-4310(00)01757-3","citationCount":"57","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1357431000017573","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 57

Abstract

Biological agents that inhibit the activity of proinflammatory cytokines are being investigated for use in the treatment of rheumatoid arthritis. Thus far, two of these agents, both of which neutralize tumor necrosis factor α (TNF-α), have received US Food and Drug Administration approval for the treatment of the disease. Etanercept is a bioengineered fusion protein of the p75 soluble TNF receptor, and infliximab is a chimeric monoclonal antibody to TNF-α. Other agents that target proinflammatory cytokines are also being developed. By allowing earlier treatment and better-tolerated long-term therapy, biologics might help slow or prevent disease progression and joint destruction.

类风湿性关节炎中的细胞因子:试验和磨难
抑制促炎细胞因子活性的生物制剂正在研究用于类风湿关节炎的治疗。到目前为止,这两种药物均能中和肿瘤坏死因子α (TNF-α),已获得美国食品和药物管理局批准用于治疗该疾病。依那西普是p75可溶性TNF受体的生物工程融合蛋白,英夫利昔单抗是TNF-α的嵌合单克隆抗体。其他针对促炎细胞因子的药物也正在开发中。通过允许早期治疗和更好耐受的长期治疗,生物制剂可能有助于减缓或预防疾病进展和关节破坏。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信